In in vivo efficacy studies in colon carcinoma CT26 tumors, ExoASO STAT6 or C/EBPβ treatment results in a reduction in the expression of STAT6 and C/EBPβ in tumor‐associated CD11b+ myeloid cells. Here, STAT6 is linked to colon carcinoma.